Skip to content
value.today

Cellular Longevity, Inc.

Total raised
$136 M
5 rounds on record
Latest round
$22 M
Oct 2024
First round on record
Jan 2020
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cellular Longevity, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$22 MNo. 5$10 to $50 million

Cellular Longevity, Inc.: Raise no. 5, Oct 2024

Investors in this round

12 investors had bought by the notice of Oct 28, 2024: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M of $33 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Celine-Lea Halioua-Haubold · Executive Officer, Director
  • Blake Scholl · Director
  • Kevin Zhang · Director
  • Laura Deming · Director
  • Linda Rhodes · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Amount Sold include conversion of the previously issued Simple Agreements for Future Equity”

Signed by Celine-Lea Halioua-Haubold, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 28, 2024. Read the notice at the SEC.

equitySEC
Mar 2024$76 MNo. 4$50 to $250 million

Cellular Longevity, Inc.: Raise no. 4, Mar 2024

Investors in this round

38 investors had bought by the notice of Mar 29, 2024: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$76 M of $76 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Celine-Lea Halioua-Haubold · Executive Officer, Director
  • Blake Scholl · Director
  • Kevin Zhang · Director
  • Laura Deming · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering and Sales Amount inclusive of converting SAFEs.”

Signed by Celine-Lea Halioua-Haubold, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 29, 2024. Read the notice at the SEC.

equitySEC
Aug 2021$28 MNo. 3$10 to $50 million

Cellular Longevity, Inc.: Raise no. 3, Aug 2021

Investors in this round

42 investors had bought by the notice of Oct 1, 2021: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$28 M of $29 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Celine-Lea Halioua-Haubold · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes the conversion of certain SAFEs”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes, including the payment of salaries and other fees to those listed in Item 3.”

Signed by Celine-Lea Halioua-Haubold, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 1, 2021. Read the notice at the SEC.

equitySEC
Sep 2020$5 MNo. 2$2 to $10 million

Cellular Longevity, Inc.: Raise no. 2, Sep 2020

Investors in this round

28 investors had bought by the notice of Jun 25, 2021: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Celine-Lea Halioua-Haubold · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Celine-Lea Halioua-Haubold, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 25, 2021. Read the notice at the SEC.

equitySEC
Jan 2020$5 MNo. 1$2 to $10 million

Cellular Longevity, Inc.: Raise no. 1, Jan 2020

Investors in this round

19 investors had bought by the notice of Jan 16, 2020: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Celine-Lea Halioua-Haubold · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Celine-Lea Halioua-Haubold, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 16, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cellular Longevity, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).

    SEC Form D · Oct 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2024

That is all the official record says: Cellular Longevity, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cellular Longevity, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 42 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cellular Longevity, Inc.
NameRoleNamed in
Celine-Lea Halioua-HauboldExecutive officerOct 2024
Blake SchollDirectorOct 2024
Celine-Lea Halioua-HauboldDirectorOct 2024
Kevin ZhangDirectorOct 2024
Laura DemingDirectorOct 2024
Linda RhodesDirectorOct 2024